Orphan drug achieves success in Phase III trial

Article

Novagali Pharma has reported positive results from a Phase III clinical study investigating the use of its drug candidate, Vekacia, as a treatment for paediatric Vernal Keratoconjunctivitis (VKC).

Novagali Pharma has reported positive results from a Phase III clinical study investigating the use of its drug candidate, Vekacia, as a treatment for paediatric Vernal Keratoconjunctivitis (VKC).

The study, led by Professor David Ben Ezra of the Hadassah Hebrew University Hospital, Jerusalem, Israel, showed that both symptoms and signs of VKC improved in patients receiving Vekacia.

Vekacia is a topical Cyclosporine A cationic emulsion, which enables efficient drug absorption in tissues of the eye. Novagali received EMEA orphan drug designation for Vekacia in the treatment of VKC in March 2006.

Based upon the success of the study, the company plans to file for European Marketing Authorization in the middle of 2007.

In other news, Novagali has also entered into a strategic collaboration with biopharmaceutical firm Topigen Pharmaceuticals. Under the terms of the agreement, Novagali will receive exclusive worldwide rights to develop and commercialize an ophthalmic product based on Topigen's multi-targeted, RNA-targeting platform technology for the treatment and prevention of allergic eye diseases.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.